🇺🇸 FDA
Patent

US 10745413

Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives

granted A61KA61K31/381A61P

Quick answer

US patent 10745413 (Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives) held by Verrica Pharmaceuticals Inc. expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Verrica Pharmaceuticals Inc.
Grant date
Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/381, A61P, A61P11/02, A61P15/00